Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
67 hedge funds and large institutions have $178M invested in Concert Pharmaceuticals, Inc. in 2015 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 29 increasing their positions, 13 reducing their positions, and 17 closing their positions.
123% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 13
12% more capital invested
Capital invested by funds: $159M → $178M (+$18.9M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 17
1% less funds holding
Funds holding: 68 → 67 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$18M |
| 2 |
SAM
Senzar Asset Management
New York
|
+$6.72M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$6.69M |
| 4 |
Millennium Management
New York
|
+$2.94M |
| 5 |
Bank of New York Mellon
New York
|
+$1.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$5.47M |
| 2 |
QF
QVT Financial
New York
|
-$3.94M |
| 3 |
ACPU
Arrowgrass Capital Partners (US)
Dover,
Delaware
|
-$2.23M |
| 4 |
Jennison Associates
New York
|
-$2.22M |
| 5 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$1.52M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Renaissance Technologies
New York
| – | -$453K | -29,900 | Closed |
|
77
Two Sigma Advisers
New York
| – | -$415K | -27,400 | Closed |
|
|
MCM
78
Moore Capital Management
New York
| – | -$379K | -25,000 | Closed |
|
|
WMSA
79
Weiss Multi-Strategy Advisers
New York
| – | -$379K | -25,000 | Closed |
|
|
BG
80
BlackRock Group
London,
United Kingdom
| – | -$353K | -23,299 | Closed |
|
|
BCM
81
BlueCrest Capital Management
St Helier,
Jersey
| – | -$341K | -22,542 | Closed |
|
82
Jane Street
New York
| – | -$308K | -20,330 | Closed |
|
83
Citadel Advisors
Miami,
Florida
| – | -$293K | -19,333 | Closed |
|
|
BJ
84
BlackRock Japan
Tokyo,
Japan
| – | -$40K | -2,663 | Closed |
|
CNCE Hedge Fund Activity: Q2 2015 in Review
67 of the 3,713 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q2 2015, worth a combined $178M — up 12% from $159M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of CNCE and 16 opened new positions — a net loss of 1 holder — while 13 trimmed existing stakes and 29 added.
The largest buyer was BVF Inc, adding an estimated $18M. The largest seller was Sphera Funds Management, cutting an estimated $5.47M.
- 67 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q2 2015, down from 68 in Q1 2015.
- Funds reported $178M of Concert Pharmaceuticals, Inc. stock for Q2 2015, up 12% quarter-over-quarter.
- 16 funds opened new Concert Pharmaceuticals, Inc. positions in Q2 2015 and 17 closed out, a net change of -1 holder.
- The largest Concert Pharmaceuticals, Inc. buyer in Q2 2015 was BVF Inc, an estimated $18M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q2 2015 was Sphera Funds Management, an estimated $5.47M sold.
Based on aggregated 13F filings for Q2 2015.